Background One of the top three pharma companies in the US was looking to develop a playbook for appropriately handling the generic competition for their specialty blockbuster therapeutic. To do this, the company needed to update their internal practices for this specialty category - different from what they were following for o...

An emerging pharma in Cambridge, MA, while undergoing Phase III clinical studies for their first commercial launch, wished to identify pharma company best practices prior to defining their own commercial program.   In order to identify specific best practices by functional area, over 30 Senior Pharma Experts (across commercial and ...

A small biopharmaceutical company had successfully completed proof-of-concept studies in the steps to develop therapeutics for the treatment of neurological conditions, including Traumatic Brain Injury (TBI), Repeat Concussion (Chronic traumatic encephalopathy or CTE) and Stroke. The company contracted Coolmeen Consulting for the development of ...